The Takeda covalent BTK inhibitor clinical candidate, TAK-020, is a highly selective oral covalent BTK inhibitor with safety and tolerability profiles that are promising for both hematologic malignancies and autoimmune…
The Takeda covalent BTK inhibitor clinical candidate, TAK-020, is a highly selective oral covalent BTK inhibitor with safety and tolerability profiles that are promising for both hematologic malignancies and autoimmune…